M1408 HCPCS Level II code: Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
M1408 is the HCPCS code for “Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
M1408Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
Short description: Gmln brca bef dx ca
HCPCS · United States
Medicare details
The indicators CMS publishes with M1408 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2025
Where M1408 sits
- 1M codesMedical services and quality measures
- 2Active code M1408Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code M1408 mean?
M1408 is the HCPCS code for “Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover M1408?
CMS lists M1408’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside M1408
All M codesM1402Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or groupM1403Patients with baseline and follow-up promis surveys documented in the medical recordM1404Patients on a therapeutic clinical trialM1405Patients with recurrence/disease progressionM1406Patients who leave the practice during the follow-up periodM1407Patients who died during the follow-up periodM1409Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosisM1410Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosisM1411Currently on first-line immune checkpoint inhibitors without chemotherapyM1412Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved…M1413Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapyM1414Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is…